The estimated Net Worth of James Loerop is at least $2.47 million dollars as of 1 February 2024. Mr. Loerop owns over 18,750 units of Anika Therapeutics stock worth over $887,186 and over the last 5 years he sold ANIK stock worth over $102,995. In addition, he makes $1,479,630 as Executive Vice President - Business Development and Strategic Planning at Anika Therapeutics.
Sign up
Mr. Loerop ANIK stock SEC Form 4 insiders trading
James has made over 7 trades of the Anika Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 18,750 units of ANIK stock worth $454,688 on 1 February 2024.
The largest trade he's ever made was exercising 18,750 units of Anika Therapeutics stock on 1 February 2024 worth over $454,688. On average, James trades about 4,980 units every 118 days since 2019. As of 1 February 2024 he still owns at least 36,585 units of Anika Therapeutics stock.
You can see the complete history of Mr. Loerop stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Loerop biography
James Loerop serves as Executive Vice President - Business Development and Strategic Planning of the Company. Mr. Loerop served as Chief Corporate Development Officer for Lupin Pharmaceuticals from September 2017 to July 2019 where he was a member of the company’s Executive Leadership Team and was responsible for global business development and corporate development activities. Prior to his work with Lupin, Jim held senior leadership roles at various companies in the pharmaceutical and life sciences industry, including at Alexion Pharmaceuticals as Senior Vice President of Global Business Development from April 2015 to September 2017, GlaxoSmithKline as Vice President of North America Business Development from September 2010 to April 2015, and Steifel Laboratories as Senior Vice President of Global Corporate Development prior to GSK’s acquisition of Stiefel. Mr. Loerop holds a B.S. in Marketing from Western Michigan University.
What is the salary of James Loerop?
As the Executive Vice President - Business Development and Strategic Planning of Anika Therapeutics, the total compensation of James Loerop at Anika Therapeutics is $1,479,630. There are no executives at Anika Therapeutics getting paid more.
How old is James Loerop?
James Loerop is 56, he's been the Executive Vice President - Business Development and Strategic Planning of Anika Therapeutics since 2019. There are 10 older and 6 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
What's James Loerop's mailing address?
James's mailing address filed with the SEC is C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087.
Insiders trading at Anika Therapeutics
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia et Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
What does Anika Therapeutics do?
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
What does Anika Therapeutics's logo look like?
Complete history of Mr. Loerop stock trades at Aclaris Therapeutics Inc et Anika Therapeutics
Anika Therapeutics executives and stock owners
Anika Therapeutics executives and other stock owners filed with the SEC include:
-
James Loerop,
Executive Vice President - Business Development and Strategic Planning -
Thomas Finnerty,
Executive Vice President of Human Resources -
Dr. Cheryl Renee Blanchard Ph.D.,
Pres, CEO & Director -
David Colleran,
Exec. VP, Gen. Counsel & Corp. Sec. -
James Loerop,
Exec. VP of Bus. Devel. & Strategic Planning -
Michael L. Levitz,
Exec. VP, CFO & Treasurer -
Thomas M. Finnerty,
Exec. VP of HR -
Joseph Bower,
Independent Chairman of the Board -
Jeffery Thompson,
Independent Director -
Raymond Land,
Independent Director -
Glenn Larsen,
Independent Director -
Cheryl Blanchard,
President, Chief Executive Officer, Director -
Susan Vogt,
Independent Director -
Dr. Cheryl R. Blanchard,
Pres, CEO & Director -
Stephen Richard,
Independent Director -
John Henneman,
Independent Director -
David Colleran,
Executive Vice President, General Counsel, Secretary -
Michael Levitz,
Chief Financial Officer, Executive Vice President, Treasurer -
Anne Nunes,
VP of Operations -
Bart Bracy,
VP of Sales & Marketing of Americas -
James Chase,
Sr. VP of International Sales & Marketing -
Charles Sherwood III,
VP & Corp. Legal Counsel -
Mark Namaroff,
Exec. Director of Investor Relations & Corp. Communications -
Alexei Goraltchouk,
Sr. VP of Operations & Project Management -
Richard Hague,
Chief Commercial Officer -
Edward S. Ahn,
Chief Tech. & Strategy Officer -
Charles H Sherwood,
President and CEO -
Sylvia Cheung,
Chief Financial Officer -
Steve E Wheeler,
Director -
Dana M. Alexander,
Chief Operations Officer -
Stephen R. Mascioli,
Chief Medical Officer -
John C Moran,
Director -
Joseph G Darling,
President and CEO; Director -
Gary P Fischetti,
Director -
Sheryl L Conley,
Director -
John W Jr Sheets,
Chief Scientific Officer -
Farmaceutici S.P.A. Fidia,
10% owner -
Peter Litman,
VP, Business Development -
William J Knight,
Chief Financial Officer -
Harvey S Sadow,
Director -
William Mrachek,
V.P., Human Resources -
Samuel F Mckay,
Director -
Eugene A Davidson,
Director -
Francesco J Luppino,
Chief Operating Officer -
Carol A Barnett,
Chief Commercial Officer -
Kevin W Quinlan,
Chief Financial Officer -
Constance H Garrison,
VP Reg.,Clinical & Qlty. Sys. -
James E O Neill,
Chief Accounting Officer -
Carol A Toth,
Vice President, R & D -
Elizabeth Chen,
Sr. VP Mktg. & Bus. Dev. -
Anne Nunes,
SVP, Chief Operations Officer -
Stephen D. Griffin,
EVP, CFO and Treasurer -
Joseph H Capper,
Director -
William R Jellison,
Director